ABSTRACT:
The increasing use of fixed-dose combinations of metformin, linagliptin, and empagliflozin for Type 2 Diabetes Mellitus (T2DM) requires reliable analytical methods for their simultaneous estimation. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is widely preferred due to its accuracy, sensitivity, and reproducibility. This review focuses on RP-HPLC method development, optimization, and validation as per ICH guidelines, along with alternative techniques such as HPTLC, UPLC, LC-MS/MS, and UV spectrophotometry. Emerging approaches including Quality by Design (QbD), stability-indicating methods, and green analytical chemistry are also highlighted.
Cite this article:
Shradha Kundan Patel, Javesh K. Patil. Review on RP-HPLC Method Development and Validation for Combined Antidiabetic Drugs: Metformin, Linagliptin and Empagliflozin. Asian Journal of Pharmacy and Technology. 2026; 16(4):421-7. doi: 10.52711/2231-5713.2026.00058
Cite(Electronic):
Shradha Kundan Patel, Javesh K. Patil. Review on RP-HPLC Method Development and Validation for Combined Antidiabetic Drugs: Metformin, Linagliptin and Empagliflozin. Asian Journal of Pharmacy and Technology. 2026; 16(4):421-7. doi: 10.52711/2231-5713.2026.00058 Available on: https://ajptonline.com/AbstractView.aspx?PID=2026-16-4-13
9. REFERENCES:
1. Choudhary N., Jain A., Sharma S. Development and validation of UV spectrophotometric method for simultaneous estimation of linagliptin and metformin. Journal of Drug Delivery and Therapeutics, 2019. DOI: 10.22270/jddt. v9i4.3358
2. Patil P.S., More H.N., Simultaneous estimation of metformin hydrochloride and linagliptin by UV spectrophotometric method. International Journal of Pharmacy and Pharmaceutical Sciences, 2015; 7(5): 320–323.
3. Ohiagu FO, Chikezie PC, Chikezie CM. Pathophysiology of diabetes mellitus complications: metabolic events and control. Biomed Res Ther. 2021 Mar 31; 8(3): 4243-57. doi: 10.15419/bmrat. v8i3.663.
4. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Feb 28; 138:271-81. doi: 10.1016/j.diabres.2018.02.023, PMID 29496507.
5. International Diabetic Federation [internet]. Type 2 diabetes. Vol. 54. p. B-1160 Brussels, Belgium.Avenue Hermann-Debroux.Available from: https://www.idf.org/aboutdiabetes/type-2 diabetes.html. [Last accessed on 20 Jul 2021]
6. Simo R, Hernandez C. Treatment of diabetes mellitus: general goals, and clinical practice management. Rev Esp Cardiol. 2002 Apr 1; 55(8): 845-60. doi: 10.1016/s0300-8932(02)76714-6, PMID 12199981.
7. Song R. Mechanism of metformin: A tale of two sites. Diabetes Care. 2016 Feb 01; 39(2): 187-9. doi: 10.2337/dci15-0013, PMID 26798149.
8. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017 Aug 03; 60(9): 1577-85. doi: 10.1007/s00125-017-4342-z, PMID 28776086.
9. Tella SH, Akturk HK, Rendell M. Linagliptin for the treatment of type 2 diabetes. Diabetes Manag. 2014; 4(1): 85-101. doi: 10.2217/dmt.13.55.
10. Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, Duan W, Zhou SF. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Oct 01; 42(10): 999 1024. doi: 10.1111/1440-1681.12455, PMID 26173919.
11. Chawla G, Chaudhary KK. A complete review of empagliflozin: most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr. 2019 May-Jun; 13(3): 2001-8. doi: 10.1016/j.dsx.2019.04.035, PMID 31235127.
12. Center for Drug Evaluation and Research [internet]. Application number: 212614Orig1s000-Clinical pharmaceutics review. Pharmacology Available and from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212614Orig1s000ClinPharmR.pdf. [Last accessed on 20 Aug 2020]
13. Lingvay I, Beetz N, Sennewald R, Schuler Metz A, Bertulis J, Loley C, Lang B, Lippert C, Lee J, Manning LS, Terada D. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgrad Med. 2020 May 04; 132(4): 337-45. doi: 10.1080/00325481.2020.1750228, PMID 32366156.
14. Li J, Lian H. Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus: A comprehensive summary for antidiabetic drugs. Arch Pharm Res. 2016 May 26; 39(6): 731-46.
15. Rena G., Hardie D.G., Pearson E.R. The mechanisms of action of metformin. Diabetologia, 2017, 60(9): 1577–1585.
16. Wishart D.S., Feunang Y.D., Guo A.C., et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Research, 2018, 46(D1): D1074–D1082.
17. Foretz M., Guigas B., Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews Endocrinology. 2019; 15: 569–589. DOI: 10.1038/s41574-019-0242-2
18. Zhou G., Myers R., Li Y. Role of AMP-activated protein kinase in mechanism of metformin action. Journal of Clinical Investigation, 2001, 108(8): 1167–1174. DOI: 10.1172/JCI13505
19. Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism, 2011, 13(1): 7–18. DOI: 10.1111/j.1463-1326.2010. 01306.x
20. Gallwitz B. Clinical use of DPP-4 inhibitors. Frontiers in Endocrinology. 2019; 10:389. DOI: 10.3389/fendo.2019.00389
21. Graefe-Mody U, Retlich S, FriedrichC.Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clinical Pharmacokinetics. 2012; 51(7): 411–427.DOI: 10.2165/11631370-000000000-00000
22. Vallon V., Thomson S.C. Targeting renal glucose reabsorption to treat hyperglycaemia: the mechanism of action of SGLT2 inhibitors. Diabetologia. 2017; 60(11): 2154–2160. DOI: 10.1007/s00125-017-4361-9
23. Ferrannini E., Mark M., Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care. 2016; 39(7): 1108–1114. DOI: 10.2337/dc16-0330
24. Heise T., Seewaldt-Becker E., Macha S. Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Therapy. 2013; 4(2): 331–345. DOI: 10.1007/s13300-013-0033-9
25. Patel IM, Chhalotiya UK, Jani HD, et al.Simultaneous quantification of empagliflozin, linagliptin and metformin hydrochloride in bulk and synthetic mixture by RP–LC method. Future Journal of Pharmaceutical Sciences. 2021; 7: 182.DOI: 10.1186/s43094-021-00332-1
26. Shah S, Kotadiya R. A novel RP-HPLC approach for simultaneous determination of dapagliflozin, linagliptin, and metformin in pharmaceutical formulations.BMC Chemistry. 2025; 19: 257. doi:10.1186/s13065-025-01620-0
27. Unade T.T., Pawar A.K. Validated stability-indicating RP-HPLC method for simultaneous determination of metformin, linagliptin and empagliflozin. International Journal of Applied Pharmaceutics. 2022. DOI: 10.22159/ijap.2022v14i2.43626
28. Nakka S., Gadthey S., Seema A., et al. Green assessment of stability-indicating RP-HPLC method for simultaneous estimation of metformin, empagliflozin and linagliptin. Asian Journal of Green Chemistry. 2024. DOI: 10.48309/AJGC.2024.466995.1533
29. Abdel Sattar O.I., Abuseada H.H.M., Emara M.S., Selim I., Ali M.A. Green evaluation of human plasma levels of metformin, linagliptin, and empagliflozin using HPLC and HPTLC methods: a pharmacokinetic study. BMC Chemistry. 2026; 20(1): 40. DOI: 10.1186/s13065-026-01726-z
30. Vankalapati K.R., Alegete P., Boodida S. Stability-indicating RP-UPLC method for simultaneous estimation of metformin, linagliptin and empagliflozin. Biomedical Chromatography. 2021; 35(4): e5019. DOI: 10.1002/bmc.5019
31. El-Desouky E.A., Abdel-Raoof A.M., Abdel-Fattah A., Abdel-Zaher A., Osman A.O.E., Abdel-Monem A.H., Morshedy S. Determination of linagliptin and empagliflozin by UPLC and HPTLC techniques aided by Lean Six Sigma approach. Biomedical Chromatography. 2021; 35(7): e5102. DOI: 10.1002/bmc.5102
32. Bhole R.P., Wankhede S.B., Pandey M., Stability indicating HPTLC method for simultaneous estimation of empagliflozin and linagliptin in pharmaceutical formulation. Analytical Chemistry Letters. 2017; 7(1): 76–85. DOI: 10.1080/22297928.2017.1279567
33. Vankalapati KR, Alegete P, Boodida S. Stability-indicating ultra performance liquid chromatography method development and validation for simultaneous estimation of metformin, linagliptin, and empagliflozin in bulk and pharmaceutical dosage form. Biomedical Chromatography. 2021; 35: e5019. https://doi.org/10.1002/bmc.5019
34. Ayoub B.M. UPLC simultaneous determination of empagliflozin, linagliptin and metformin in pharmaceutical dosage forms. RSC Advances, 2015, 5:95703–95709. DOI: 10.1039/C5RA17231D
35. Gurrala S., Raj S., Subrahmanyam C.V.S., Anumolu P.D. Quality-by-Design approach for chromatographic analysis of metformin, empagliflozin and linagliptin. Journal of Chromatographic Science. 2022; 60(1):68–80. DOI: 10.1093/chromsci/bmab030
36. Abdel Sattar O.I., Abuseada H.H.M., Emara M.S., Selim I., Ali M.A. Simultaneous determination of metformin, linagliptin and empagliflozin in human plasma using LC–MS/MS: application to pharmacokinetic study. BMC Chemistry. 2026; 20(1): 40. DOI: 10.1186/s13065-026-01726-z
37. El-Bagary R.I., Elkady E.F., Ayoub B.M. Liquid chromatography–tandem mass spectrometric method for determination of antidiabetic drugs in human plasma. Microchemical Journal. 2019; 147: 556–565. DOI: 10.1016/j.microc.2019.03.047
38. Patel IM, Chhalotiya UK, Jani HD, et al. Simultaneous quantification of empagliflozin, linagliptin and metformin hydrochloride in bulk and synthetic mixture by RP–LC method. Future Journal of Pharmaceutical Sciences. 2021; 7: 182.DOI: 10.1186/s43094-021-00332-1 fig no.4
39. Zhang W., Han Y., Wang Y., et al. Simultaneous quantification of metformin and related antidiabetic drugs in plasma by LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 2018; 152: 63–71. DOI: 10.1016/j.jpba.2018.01.023
40. Chaudhari V., Patil P., Deshmukh P. Development and validation of UV spectrophotometric method for estimation of empagliflozin in bulk and pharmaceutical dosage form. Asian Journal of Pharmaceutical Analysis. 2018. DOI: 10.5958/2231-5675.2018.00015.2
41. Patel K, Patel N, Patel M. Simultaneous estimation of metformin and empagliflozin by UV spectrophotometric methods. World Journal of Pharmacy and Pharmaceutical Sciences. 2019; 8(6): 1048–1056.